Treatment for Malignant Pleural Mesothelioma Gets FDA Approval
Treatment for Malignant Pleural Mesothelioma Gets FDA Approval The Food and Drug Administration has approved (Novocure) in combination with plus platinum-based for first-line treatment of unresectable, pleural mesothelioma (MPM). The Treatment for Malignant is a non-invasive, median progression free survival endpoint) was 7. 6 The study also that combining with did not result in increase in serious adverse mild to moderate skin was most common adverse effect. The majority of well-differentiated papillary mesothelioma tumors develop in women, specifically in the abdominal cavity. Less commonly, doctors have found WDPM tumor growth on several of the body’s protective membranes, including the pleura (lining of the lungs), pericardium (heart sac) and tunica vaginalis (lining of the testes). From a medical standpoint, these tumors are practically benign. Studies have reported WDPM turning into malignant mesothelioma over time, although the chance of this happening is unlikely. S...